HSP-CAR-30

N/A

Report date: 2022/03/11 17:07:10

Base Information

Drug NameHSP-CAR-30
Drug Alias NameHSP-CAR-30
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-CellHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFundació Institut De Recerca De L
China Registration ClassN/A

Develop Information

Active CompaniesFoundation Of The Research Institute Of The Hospital De La Santa Creu I Sant Pau
Inactive CompaniesJosep Carreras Leukaemia Research InstituteInstituto De Salud Carlos Iii
Active IndicationsLymphoma, T-CellHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A